China’s regulatory agency has approved the launch of Genron’s Phase I clinical trial to test its immunotherapy candidate, A-319, in patients with acute lymphoblastic leukemia (ALL) and B-cell lymphoma. A-319 is an antibody that binds the two targets at the same time: the CD19 protein, highly present at the surface of healthy B-cells and many leukemia and lymphoma cells, and the CD13, found on a large group of T-cells. Follow the link to the Lymphoma News Today article.
Generon (Shanghai) Corporation Ltd., a biotech company, engages in the discovery, development, and production of biomedicines for customers in China and internationally. It focuses on the development of therapeutic recombinant proteins to treat cancer, and autoimmune and inflammatory diseases. The company is based in Shanghai, China.